Says 2026 will be a year of “accelerated growth and impact.” Says has “unrivaled” pipeline of medicines. Comments taken from Q4 earnings conference call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Options Volatility and Implied Earnings Moves Today, January 21, 2026
- JNJ Earnings: Johnson & Johnson Stock Falls Despite Q4 Revenue Beat
- Genmab reports worldwide net sales of Darzalex in 2025 totaled $14.351B
- Johnson & Johnson reports Q4 adjusted EPS $2.46, consensus $2.46
- Johnson & Johnson sees FY26 adjusted EPS $11.43-$11.63, consensus $11.49